Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

Daniel J. DeAngelo, MD, PhD

Medical Oncology

Make an Appointment
Watch Video

Daniel J. DeAngelo, MD, PhD americas top doctors


  • Chief, Division of Leukemia
  • Institute Physician
  • Professor of Medicine, Harvard Medical School


Clinical Interests

  • CAR T-cell therapy
  • Leukemias
  • Mastocytosis
  • Myelodysplastic syndromes
  • Myeloproliferative disorders

Diseases Treated

Contact Information

  • Appointments617-632-6028 (new)
    617-582-7386 x1 (follow-up)
  • Office Phone Number617-582-8410
  • Fax617-632-6771


Dr. DeAngelo received his MD and PhD from Albert Einstein College of Medicine in 1993, followed by residency in internal medicine at Massachusetts General Hospital. He served a clinical fellowship in hematology and oncology at the Brigham and Women's Hospital and Dana-Farber Cancer Institute, where he joined the staff in 1999.

Board Certification:

  • Hematology, 2000
  • Internal Medicine
  • Medical Oncology, 1999


  • Brigham and Women's Hospital, Hematology & Oncology


  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • Albert Einstein College of Medicine


Treating Leukemias, Myelodysplasia, and Myeloproliferative Disorders

The Adult Leukemia Group is responsible for the diagnosis and treatment of patients with acute and chronic leukemia, myelodysplastic syndrome (MDS), and other stem cell hematopoietic disorders. Our clinical research centers around phase I, II, and III clinical trials in these patients.We recently studied a series of patients with idiopathic hypereosinophilic syndrome (IHES). In collaboration with Drs. Cools and Gilliland, we identified a target gene, the FIP1L1-PDGFRA fusion gene, which is a consequence of an interstitial chromosomal deletion. This finding has led to the explanation of the molecular basis of IHES.Our group is currently working on the development of small molecules to treat acute and chronic leukemias and myelodysplasia. We are testing several small molecules in patients with relapsed or refractory acute myelogenous leukemia, studying the compounds PKC-412, CEP-701, and MLN-518 that specifically inhibit FLT3. Mutations in the FLT3 gene, which encodes a receptor tyrosine kinase, are thought to confer a poor prognosis in patients with acute myelogenous leukemia. We also have clinical trials under way that test histone deacetylase inhibitors in advanced hematologic malignancies. Our approach is to bring novel therapeutic agents to the forefront in the treatment of patients with acute and chronic leukemia, MDS, and myeloproliferative disorders.In addition, our group has been focused on the treatment of acute lymphoblastic leukemia (ALL). We are the lead coordinating site for a large clinical trial using dose-intense pediatric-like regimens for adult patients with ALL. We are also testing novel Notch inhibitor molecules for patients with relapsed or refractory T-cell ALL.


Dana-Farber Cancer Institute
450 Brookline Avenue
Dana D1B30
Boston, MA 02215
Get Directions